John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health, discusses management challenges still facing providers treating multiple myeloma.
John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health, discusses management challenges still facing providers treating multiple myeloma.
Transcript
While the multiple myeloma treatment landscape has improved, what are the biggest management challenges providers treating the diseases still face?
In the las half a decade, there have been 5 or 6 drugs that have been approved for multiple myeloma and even more combinations of drugs, and in this day and era, we have more and more options available to patients, but we don’t understand how to best use those options. We need more information about the role of transplant is, especially in an era where we have very high MRD [minimal residual disease]- negativity.
We need more information about the duration of treatment, especially when you’re MRD negative, because these drugs could be used for the rest of one’s life, and if there’s no added value and there’s accumulated toxicity or increased risk of cardiopulmonary toxicity or increased risk of cancer, patients need to weigh those and physicians need to weigh those. In the absence of information, how long do you treat patients? We’re operating in the dark. So, I think those are some of the areas: what’s the role of transplant, what’s the role of multiple drug combinations, the relative benefits, and then how long do we need to treat people who have a very good response?
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen